Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNX-2401 intratumoral monotherapy for recurrent or refractory pediatric high-grade brain tumors
NL-OMON58892Phase 2Not yet recruiting
- Sponsor
- Clínica Universidad de Navarra
- Start
- Feb 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ad5-D24RGD in brain cancer, glioma, ependymoma and 1 more, sponsored by Clínica Universidad de Navarra. Primary endpoint: Overall response rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Ad5-D24RGD
03
Conditions
brain cancergliomaependymomaembryonal tumors
Beyond the preview
Go deeper on NL-OMON58892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58892.